2. Search Result
Search Result
Results for "

Haemophilus influenzae

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

3

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0958
    Mupirocin
    1 Publications Verification

    BRL-4910A; Pseudomonic acid

    		 Bacterial Antibiotic Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin
  • HY-17593
    Solithromycin
    3 Publications Verification

    CEM-101; OP-1068

    		 Bacterial Antibiotic Infection
    Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .
    Solithromycin
  • HY-B1228
    Ribostamycin sulfate
    1 Publications Verification

    Vistamycin sulfate

    		 Antibiotic PDI Infection
    Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant KD of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .
    Ribostamycin sulfate
  • HY-116815
    Lalistat 1
    2 Publications Verification

    		 Beta-lactamase Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
    Lalistat 1
  • HY-B1325
    Cefuroxime axetil

    		Bacterial Antibiotic Infection Inflammation/Immunology
    Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .
    Cefuroxime axetil
  • HY-121329
    Carumonam

    AMA-1080; Ro 17-2301

    		 Penicillin-binding protein (PBP) Antibiotic Bacterial Infection
    Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis .
    Carumonam
  • HY-A0111
    Cefetamet
    1 Publications Verification

    Ro 15-8074; Deacetoxycefotaxime

    		 Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite Infection
    Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC50 for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .
    Cefetamet
  • HY-W108875
    Mupirocin lithium
    1 Publications Verification

    BRL-4910A lithium; Pseudomonic acid lithium

    		 Antibiotic Bacterial Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin lithium
  • HY-N7101
    Cefpodoxime Proxetil

    U-76,252; CS-807

    		 Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil
  • HY-159688
    Cefditoren
    1 Publications Verification

    		 Antibiotic Bacterial Penicillin-binding protein (PBP) Interleukin Related Infection
    Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis .
    Cefditoren
  • HY-135221
    Cefcapene pivoxil hydrochloride

    		Bacterial Antibiotic Infection
    Cefcapene pivoxil hydrochloride, the pivalate ester prodrug form of Cefcapene, is an orally active third-generation cephalosporin with a wide spectrum of anti-bacterial activity. Cefcapene pivoxil hydrochloride has the potential for the palmoplantar pustulosis (PPP) research .
    Cefcapene pivoxil hydrochloride
  • HY-B1149A
    Bacampicillin (hydrochloride)

    		Drug Derivative Bacterial Antibiotic Infection
    Bacampicillin hydrochloride is an orally active semi-synthetic aminopenicillin derivative, prodrug and bactericide that is readily inactivated by β-lactamases. Bacampicillin hydrochloride is hydrolyzed by carboxylester hydrolases and non-specific esterases in the gastrointestinal wall and plasma to form Ampicillin (HY-B0522), and produces higher levels of Ampicillin in rodents in vivo. Bacampicillin hydrochloride exhibits bactericidal activity against Gram-positive and Gram-negative bacteria. Bacampicillin hydrochloride can be used in studies related to bacterial infections .
    Bacampicillin (hydrochloride)
  • HY-126463
    LolCDE-IN-4

    		Bacterial Infection
    LolCDE-IN-4 (Compound 1) is exhibits antibacterial efficacy against gram negative bacteria Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae, through inhibition LolCDE complex and disruption of lipoproteins release from the inner membrane .
    LolCDE-IN-4
  • HY-159687
    Nafithromycin

    WCK 4873

    		 Antibiotic Bacterial Infection
    Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .
    Nafithromycin
  • HY-U00380
    Tigemonam

    		Antibiotic Beta-lactamase Bacterial Infection
    Tigemonam is an orally active monobactam antibiotic with a Ki of 0.86 μM against Enterobacter cloacae P99 β-lactamase and 50.8 μM against Escherichia coli TEM-1 β-lactamase. Tigemonam binds to penicillin-binding proteins 1a, 3, and 4, inhibits bacterial cell wall synthesis, and exhibits bactericidal activity against aerobic gram-negative bacteria including Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae. Tigemonam resists hydrolysis by multiple β-lactamase enzymes, reduces bacterial load in systemic, pyelonephritic, lung, and thigh muscle infections in rodents, and shows minimal difference between minimum inhibitory and bactericidal concentrations. Tigemonam can be used for the research of gram-negative bacterial infections, acute pyelonephritis, lung infection, and thigh muscle infection .
    Tigemonam
  • HY-W023253
    Biclotymol

    		Bacterial Fungal Infection Inflammation/Immunology
    Biclotymol is an antimicrobial agent against gram-positive cocci. Biclotymol inhibits Streptococcus pneumoniae and Haemophilus influenzae, with MIC of 150 and 150 μM. Biclotymol exhibits anti-inflammatory and analgesic activity and ameliorates the otolaryngology infection and throat sore .
    Biclotymol
  • HY-19428A
    Ranbezolid hydrochloride

    RBx-7644

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid hydrochloride
  • HY-19428
    Ranbezolid

    RBx7644 free base

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid
  • HY-W743473
    Cefetamet-d3

    Ro 15-8074-d3; Deacetoxycefotaxime-d3

    		 Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Drug Metabolite Infection
    Cefetamet-d3 (Ro 15-8074-d3; Deacetoxycefotaxime-d3) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC50 for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .
    Cefetamet-d3
  • HY-121195
    Apalcillin

    PC-904

    		 Bacterial Infection
    Apalcillin (PC-904) in combination with Ro 48-1220, a penam sulfone β-lactamase inhibitor, demonstrated broad-spectrum activity against gram-negative aerobic and anaerobic bacteria, excluding Klebsiella oxytoca. It exhibited potent activity against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae, with effective MICs (11 μg/mL). The combination also inhibited Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species at low MICs (0.25 to 4 μg/mL). However, its efficacy against oxacillin-resistant staphylococci and certain gram-positive organisms was limited. Apalcillin/Ro 48-1220 showed comparable efficacy to piperacillin/tazobactam against some extended-spectrum β-lactamase-producing Escherichia coli but was less effective against SHV-type β-lactamases .
    Apalcillin
  • HY-111127
    LY164846

    		Antibiotic Bacterial Infection
    LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin (HY-B0522)-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin (HY-121544)-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections .
    LY164846
  • HY-105213
    YM-17K

    MC-352

    		 Antibiotic Bacterial Infection
    YM-17K (MC-352) is a macrolide antibiotic. YM-17K exhibits antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria. YM-17K exhibits stable activity in serum and is less affected by pH values .
    YM-17K
  • HY-161788
    DNA Gyrase-IN-11

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC50 is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC50 of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .
    DNA Gyrase-IN-11
  • HY-W747311
    Ritipenem

    		Antibiotic Bacterial Penicillin-binding protein (PBP) Infection
    Ritipenem is a penicillin antibiotic, that targets penicillin-binding protein with good affinity (IC50 in levels of ng/mL), and exhibits antibacterial properties. Ritipenem exhibits antiviral activity against Haemophilus influenzae .
    Ritipenem
  • HY-W744633
    Cefdaloxime

    		Drug Metabolite Bacterial Infection
    Cefdaloxime is an orally active cephalosporin and HR-916 ester metabolite. Cefdaloxime has a broad spectrum of activity against pathogens such as the majority of members of the family Enterobacteriaceae, staphylococci, Streptococcus spp., Neisseria gonorrhoeae, Moraxella catarrhalis, Haemophilus influenzae .
    Cefdaloxime
  • HY-135221R
    Cefcapene pivoxil hydrochloride (Standard)

    		Reference Standards Bacterial Antibiotic Infection
    Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Cefcapene pivoxil hydrochloride (Standard)
  • HY-123508
    PD 131628

    		Drug Metabolite Bacterial Infection
    PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC90s ranging from 0.004 to 0.008 mg/L .
    PD 131628
  • HY-17593R
    Solithromycin (Standard)

    CEM-101 (Standard); OP-1068 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Solithromycin (Standard) is the analytical standard of Solithromycin. This product is intended for research and analytical applications. Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .
    Solithromycin (Standard)
  • HY-B0958R
    Mupirocin (Standard)

    BRL-4910A (Standard); Pseudomonic acid (Standard)

    		 Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin (Standard)
  • HY-125579
    Ro 25-0534

    		Bacterial Infection
    Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC90: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC90: 1-2 μg/mL), Haemophilus influenzae (MIC90: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC90: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC90: 2-4 μg/mL) .
    Ro 25-0534
  • HY-W108875R
    Mupirocin lithium (Standard)

    BRL-4910A lithium (Standard); Pseudomonic acid lithium (Standard)

    		 Antibiotic Bacterial Reference Standards Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin (lithium) (Standard) is the analytical standard of Mupirocin lithium (HY-W108875). This product is intended for research and analytical applications. Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin lithium (Standard)
  • HY-A0111A
    Cefetamet sodium

    Ro15-8074/001; Deacetoxycefotaxime sodium

    		 Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite Infection
    Cefetamet (Ro 15-8074) sodium is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet sodium binds to bacterial penicillin-binding protein (PBP) (IC50 for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet sodium has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet sodium kills and lyses Treponema pallidum. Cefetamet sodium can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .
    Cefetamet sodium
  • HY-A0111B
    Cefetamet hydrochloride

    Ro 15-8074 hydrochloride; Deacetoxycefotaxime hydrochloride

    		 Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite Infection
    Cefetamet (Ro 15-8074) hydrochloride is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet hydrochloride binds to bacterial penicillin-binding protein (PBP) (IC50 for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet hydrochloride has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet hydrochloride kills and lyses Treponema pallidum. Cefetamet hydrochloride can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .
    Cefetamet hydrochloride
  • HY-B1894
    Cefetamet pivoxyl

    Ro 15-8075 free base

    		 Antibiotic Bacterial Infection
    Cefetamet pivoxyl (Ro 15-8075 free base) is an orally active cephalosporin Antibiotic and a prodrug of Cefetamet (HY-A0111). After ingestion, Cefetamet pivoxyl is hydrolyzed by gastrointestinal esterases to form Cefetamet. Cefetamet pivoxyl is primarily active against aerobic Gram-negative bacteria (such as Enterobacteriaceae, *Neisseria*, *Haemophilus*) and some Gram-positive bacteria (such as non-enterococcal streptococci). Cefetamet pivoxyl exhibits potent in vivo antibacterial activity against strains of Gram-positive bacteria (S. pyogenes) and Gram-negative bacteria (E. coli, K. pneumoniae, S. marcescens, P. vulgaris, P. mirabilis, H. influenzae) .
    Cefetamet pivoxyl
  • HY-A0111R
    Cefetamet (Standard)

    Ro 15-8074 (Standard); Deacetoxycefotaxime (Standard)

    		 Reference Standards Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite Infection
    Cefetamet (Standard) is the analytical standard of Cefetamet (HY-A0111). This product is intended for research and analytical applications. Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC50 for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .
    Cefetamet (Standard)
  • HY-N7101R
    Cefpodoxime Proxetil (Standard)

    U-76,252 (Standard); CS-807 (Standard)

    		 Reference Standards Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil (Standard) is the analytical standard of Cefpodoxime Proxetil. This product is intended for research and analytical applications. Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil (Standard)
  • HY-N7101S
    Cefpodoxime proxetil-d7

    U-76-d7,252-d7; CS-807-d7

    		 Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime proxetil-d7 (U-76-d7,252-d7; CS-807-d7) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime proxetil-d7
  • HY-105560
    Cefcanel

    		Bacterial Beta-lactamase Infection
    Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases .
    Cefcanel
  • HY-129914
    Cefcanel daloxate

    KY-109 free base

    		 Bacterial Infection
    Cefcanel daloxate (KY-109 (free base)) is an orally active cephalosporin prodrug against Gram-positive bacteria and Haemophilus influenzae. Cefcanel daloxate is promising for research of uremia .
    Cefcanel daloxate
  • HY-U00092A
    BAY-Y 3118 hydrochloride

    		Bacterial Infection
    BAY-Y 3118 hydrochloride is a quinolone antibacterial agent. BAY-Y 3118 hydrochloride has a broad antibacterial spectrum in vitro. BAY-Y 3118 hydrochloride exhibits high activity against gram-positive cocci and anaerobes. BAY-Y 3118 hydrochloride shows moderate activity against Enterobacteriaceae and Pseudomonas aeruginosa. BAY-Y 3118 hydrochloride can be used in the research of infectious diseases .
    BAY-Y 3118 hydrochloride
  • HY-111034
    CGP 31523A

    		Antibiotic Bacterial Infection
    CGP 31523A is a broad-spectrum aminothiazole cephalosporin. CGP 31523A exhibits potent inhibitory effects on Enterobacteriaceae, Neisseria, Haemophilus influenzae, and Streptococcus (except Enterococcus faecalis), among others. CGP 31523A can be hydrolyzed by the common Escherichia coli type Ic β-lactamase, but is stable against the Ia type enzyme. CGP 31523A is neither an effective β-lactamase inhibitor nor does it induce the production of β-lactamase. CGP 31523A can be used for studying infections caused by Gram-negative bacteria (including drug-resistant strains) .
    CGP 31523A
  • HY-185351
    Ampicillin sodium and Sulbactam sodium

    Ampicillin/Sulbactam combination

    		 Bacterial Antibiotic Infection
    Ampicillin sodium and Sulbactam sodium are formed by mixing HY-B0522A Ampicillin sodium with HY-B0334A Sulbactam sodium (each 1.5 g of this product contains 1 g amoxicillin sodium and 0.5 g sulbactam sodium). Ampicillin is a β-lactam antimicrobial, whereas sulbactam is a β-lactamase inhibitor. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. However, ampicillin is degraded by beta-lactamases. The combination of ampicillin and sulbactam demonstrates synergy in addressing bacterial strains resistant to ampicillin, thus providing broader coverage. Bacteria susceptible to ampicillin/sulbactam include Haemophilus influenzae, Escherichia coli, Acinetobacter, Klebsiella, Staphylococcus aureus, Enterobacter, and anaerobes.
    Ampicillin sodium and Sulbactam sodium
  • HY-181107
    DNA Gyrase/ribosomes-IN-1

    		Bacterial DNA/RNA Synthesis Cytochrome P450 Infection
    DNA Gyrase/ribosomes-IN-1 is a bacterial ribosome and DNA gyrase inhibitor, with IC50 values of 1.11 μM and 3.31 μM, respectively. DNA Gyrase/ribosomes-IN-1 also inhibits CYP3A4, with an IC50 of 18.5 μM, and exhibits stability in mouse plasma and liver microsomes. DNA Gyrase/ribosomes-IN-1 inhibits bacterial protein synthesis by interacting with ribosomal RNA and associated sites. DNA Gyrase/ribosomes-IN-1 suppresses bacterial DNA replication by interacting with the gyrase complex. DNA Gyrase/ribosomes-IN-1 restores activity against macrolide-resistant, erm-mediated Gram-positive pathogens and enhances activity against Gram-negative bacteria such as Haemophilus influenzae and Moraxella catarrhalis. DNA Gyrase/ribosomes-IN-1 can be used in research on community-acquired bacterial pneumonia .
    DNA Gyrase/ribosomes-IN-1
  • HY-W683763A
    Olamufloxacin methanesulfonate

    HSR-903

    		 Bacterial Infection
    Olamufloxacin (HSR-903) methanesulfonate is an orally active fluoroquinolone antibacterial agent. Olamufloxacin methanesulfonate inhibits DNA supercoiling activity. Olamufloxacin methanesulfonate exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin methanesulfonate can be used for the research of bacterial infections .
    Olamufloxacin methanesulfonate
  • HY-W683763
    Olamufloxacin

    HSR-903 free base

    		 Bacterial Infection
    Olamufloxacin (HSR-903) is an orally active fluoroquinolone antibacterial agent. Olamufloxacin inhibits DNA supercoiling activity. Olamufloxacin exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin can be used for the research of bacterial infections .
    Olamufloxacin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: